Target- |
Mechanism- |
|
|
Active Indication- |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Two-Part Randomized Double-Blinded Placebo-Controlled, Phase 1 Study of Single and Multiple Ascending Doses of MH-001 in Healthy Participants
First-in-Human study to demonstrate the safety and tolerability of single- and multiple-ascending doses of MH-001 in Healthy Volunteers (HVs)
100 Clinical Results associated with Vespina Lifesciences, Inc.
0 Patents (Medical) associated with Vespina Lifesciences, Inc.
100 Deals associated with Vespina Lifesciences, Inc.
100 Translational Medicine associated with Vespina Lifesciences, Inc.